ProfileGDS5678 / 1421748_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 59% 59% 54% 66% 59% 62% 57% 58% 59% 56% 59% 59% 59% 65% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5625859
GSM967853U87-EV human glioblastoma xenograft - Control 23.5419359
GSM967854U87-EV human glioblastoma xenograft - Control 33.3363654
GSM967855U87-EV human glioblastoma xenograft - Control 43.9600766
GSM967856U87-EV human glioblastoma xenograft - Control 53.4985559
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7698362
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.558357
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5155858
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5229559
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3929356
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.542759
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5269359
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5438859
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.9174265